Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Asian Pacific Journal of Tropical Medicine ; 15(9):400-409, 2022.
Article in English | EMBASE | ID: covidwho-2080621


Objective: To evaluate long-term effects of COVID-19, and to determine the risk factors in long-COVID in a cohort of the Turkish Thoracic Society (TTS)-TURCOVID multicenter registry. Method(s): Thirteen centers participated with 831 patients;504 patients were enrolled after exclusions. The study was designed in three-steps: (1) Phone questionnaire;(2) retrospective evaluation of the medical records;(3) face-to-face visit. Result(s): In the first step, 93.5% of the patients were hospitalized;61.7% had a history of pneumonia at the time of diagnosis. A total of 27.1% reported clinical symptoms at the end of the first year. Dyspnea (17.00%), fatigue (6.30%), and weakness (5.00%) were the most prevalent long-term symptoms. The incidence of long-term symptoms was increased by 2.91 fold (95% CI 1.04-8.13, P=0.041) in the presence of chronic obstructive pulmonary disease and by 1.84 fold (95% CI 1.10-3.10, P=0.021) in the presence of pneumonia at initial diagnosis, 3.92 fold (95% Cl 2.29-6.72, P=0.001) of dyspnea and 1.69 fold (95% Cl 1.02-2.80, P=0.040) fatigue persists in the early-post-treatment period and 2.88 fold (95% Cl 1.52-5.46, P=0.001) in the presence of emergency service admission in the post COVID period. In step 2, retrospective analysis of 231 patients revealed that 1.4% of the chest X-rays had not significantly improved at the end of the first year, while computed tomography (CT) scan detected fibrosis in 3.4%. In step 3, 138 (27.4%) patients admitted to face-to-face visit at the end of first year;at least one symptom persisted in 49.27% patients. The most common symptoms were dyspnea (27.60%), psychiatric symptoms (18.10%), and fatigue (17.40%). Thorax CT revealed fibrosis in 2.4% patients. Conclusion(s): COVID-19 symptoms can last for extended lengths of time, and severity of the disease as well as the presence of comorbidities might contribute to increased risk. Long-term clinical issues should be regularly evaluated after COVID-19. Copyright © 2022 Asian Pacific Journal of Tropical Medicine Produced by Wolters Kluwer Medknow.

Acta Medica Mediterranea ; 37(5):2483-2494, 2021.
Article in English | Scopus | ID: covidwho-1449388


Background: In this study, we aimed to assess effectiveness of the major preventive measures to control of COVID-19 pandemic in six countries Methods: Case numbers and intervention times of countries documented by the World Health Organization were used. A natural estimation plot (M0) was constructed for the initial period with no interventions. Estimation models (M1, 2, 3, etc.) to reach the threshold number of cases (5000 cases/day) were calculated for each intervention. The effectiveness of intervention was measured by the magnitude of displacement of its prediction plot to the right of the M0 plot. Results: In the absence of interventions (M0 model), Turkey had the earliest threshold time (26.81 days), whereas France had the longest (58.72 days). Event-specific effect size was the largest for suspension of formal education in all countries, except for Italy (0.03). The effect size of closing the schools was the largest in Iran (16.52) and France (6.75) and the least in Spain (0.45) and Italy (0.03). Turkey (3.82) and the UK (6.07) had a medium effect size. The closure of workplaces had the largest effect size in the UK (4.27) and Italy (4.20). A recommendation to stay at home policy had the lowest impact in the UK (0.58). A second increase was noted in the case trend in Iran after lifting the containment measures. Conclusions: Major interventions are effective and should be adopted early to achieve a higher health impact;however premature easing of restrictions can lead to a loss in controlling the spread of pandemic. © 2021 A. CARBONE Editore. All rights reserved.